ErbB inhibitors as neoadjuvant therapy for triple-positive breast cancer: a network meta-analysis.

ABSTRACT:

Background

Evidence on the effectiveness of ErbB inhibitor interventions for women with triple-positive breast cancer (TPBC) is scarce. Exposure to hormone receptors was reported to eclipse targeted intervention effectiveness. Here, we aimed to explore the optimum targeted regimen for TPBC.

Methods

We conducted a thorough search of the literature focusing on neoadjuvant targeted therapy with both hormone receptor-positive and HER2 (ErbB2)-positive patients and performed a network meta-analysis comparing the regimens using a random-effects model. The rate of pathological complete response (pCR) (ypT0/is) was the primary outcome. The odds ratio (OR) with 95% confidence interval (CI) was used to assess the association among twelve regimens.

Results

Thirteen studies meeti

SUBMITTER: Chen D 

PROVIDER: S-EPMC8661156 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature